What is ForSight Robotics?
ForSight Robotics is a pioneering medical technology firm dedicated to the advancement of ophthalmic surgery through its proprietary ORYOM platform. By integrating sophisticated robotic systems with high-fidelity imaging and surgical guidance, the company aims to standardize complex eye procedures, thereby enhancing patient outcomes and surgical efficiency. The firm operates at the intersection of robotics, artificial intelligence, and microsurgery, addressing a critical need for precision in vision-restoring interventions. With a focus on scalability and clinical safety, ForSight Robotics is effectively bridging the gap between traditional manual surgical techniques and the future of automated, data-driven healthcare.
How much funding has ForSight Robotics raised?
ForSight Robotics has raised a total of $190M across 3 funding rounds:
Angel/Seed
$10M
Series A
$55M
Series B
$125M
Angel/Seed (2021): $10M with participation from MITHRIL CAPITAL PLC and Eclipse Ventures Incorporated
Series A (2022): $55M led by MITHRIL CAPITAL, Adani, and Eclipse Ventures
Series B (2025): $125M supported by Eclipse Automation and Adani
Key Investors in ForSight Robotics
Adani
A diversified industrial conglomerate with extensive experience in infrastructure, energy, and logistics, providing strategic support for large-scale technological deployment.
Eclipse Ventures
A venture capital firm focused on the intersection of physical and digital industries, specializing in backing companies that build complex, hardware-centric solutions.
MITHRIL CAPITAL
An investment vehicle focused on identifying and scaling high-growth opportunities within the technology, media, and telecommunications sectors.
What's next for ForSight Robotics?
With the successful closure of its latest financing round, ForSight Robotics is poised to transition into a critical phase of global market entry and regulatory scaling. The strategic focus will likely shift toward securing international clinical certifications and expanding the deployment of the ORYOM platform across major surgical centers. Furthermore, the company is expected to invest heavily in research and development to refine its robotic interface, ensuring that its technology remains at the forefront of the ophthalmic surgical market. As the firm matures, the emphasis will remain on demonstrating long-term clinical efficacy and building a sustainable ecosystem for robotic-assisted vision care, ultimately aiming to set a new standard for surgical precision in the ophthalmology sector.
See full ForSight Robotics company page
